Journal
TRENDS IN CANCER
Volume 2, Issue 6, Pages 286-294Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2016.05.002
Keywords
-
Categories
Funding
- National Institutes of Health [R01 CA201246, R01 CA161891]
- Breast Cancer Research Foundation
- Chemotherapy Foundation
- USA Department of Defense Breast Cancer Research Program [W81XWH-11-1-0530]
- Breast Cancer Research Foundation.
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICI) are effective in cancer treatment. A preexisting immune response demonstrated by significant pretreatment tumor lymphocytic infiltration is a prerequisite for response. Within such infiltrated tumors, referred to as 'hot' tumors, ICI rescue the activity of antitumor T cells. By contrast, 'cold' tumors lack lymphocytic infiltration and are refractory to immunotherapy. Preclinical data show that radiotherapy sensitizes refractory tumors to ICI by recruiting antitumor T cells. Despite the growing number of clinical studies testing the ability of radiation to enhance immunotherapy, clinical evidence that it converts cold tumors into responsive ones remains elusive. Here, we review evidence that radiotherapy is not only an occasional enhancer of the effects of immunotherapy, but also a 'game changer', and propose a blueprint to test this.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available